A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase I Consortium report

Pediatric Blood and Cancer

Volumn 62, Issue 5, 2015, Pages 751-758

  Kolb, E Anders ^a   Sampson, Valerie ^a   Stabley, Deborah ^a   Walter, Alexa ^a   Sol Church, Katia ^a   Cripe, Timothy ^b   Hingorani, Pooja ^c   Ahern, Charlotte Hsieh ^d   Weigel, Brenda J ^e   Zwiebel, James ^f   Blaney, Susan M ^d  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c PHOENIX CHILDREN'S HOSPITAL   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Pediatric cancer; Phase 1; Pirotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; PELAREOREP; VIRUS RNA; ALKYLATING AGENT;

ABDOMINAL PAIN; ACIDOSIS; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN TUMOR; CANCER FATIGUE; CANCER IMMUNOTHERAPY; CANCER PAIN; CANCER PATIENT; CANCER RECURRENCE; CHILD; CHILDHOOD CANCER; CHILL; CLINICAL ARTICLE; DIARRHEA; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERNATREMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REOVIRIDAE; RESPIRATORY FAILURE; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VIRAL CLEARANCE; CANCER STAGING; CLINICAL TRIAL; DRUG RESISTANCE; FOLLOW UP; MAXIMUM TOLERATED DOSE; MULTIMODALITY CANCER THERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; SALVAGE THERAPY; TUMOR RECURRENCE; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PROGNOSIS; REOVIRIDAE; SALVAGE THERAPY; YOUNG ADULT;

EID: 84925395860     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25464     Document Type: Article

References (40)

1. Tyler KL, Fields BN. Virology. (2 ed.). New York: Raven Press.
2. Bodkin DK, Nibert ML, Fields BN. Proteolytic digestion of reovirus in the intestinal lumens of neonatal mice. J Virol 1989; 63:4676-4681.
3. Rosen L, Evans HE, Spickard A. Reovirus infections in human volunteers. Am J Hyg 1963; 77:29-37.
4. Rubin DH, Kornstein MJ, Anderson AO. Reovirus serotype 1 intestinal infection: A novel replicative cycle with ileal disease. J Virol 1985; 53:391-398.
5. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J 1998; 17:3351-3362.
6. Wolf JL, Kauffman RS, Finberg R, Dambrauskas R, Fields BN, Trier JS. Determinants of reovirus interaction with the intestinal M cells and absorptive cells of murine intestine. Gastroenterology 1983; 85:291-300.
7. Minuk GY, Rascanin RW, Paul RW, Lee PWK, Buchan K, Kelly JK. Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 1987; 5:8-13.
8. Minuk GY, Paul RW, Lee PW. The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J Med Virol 1985; 16:55-60.
9. Jackson GG, Muldoon RL. Viruses causing common respiratory infections in man. J Infect Dis 1973; 127:328-355.
10. Stanley NF. Comparative diagnosis of viral diseases. New York: Academic Press; 1977.
11. Tai JH, Williams KM, Edwards KM, Wright PF, Crowe JE, Dermody TS. Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J Infect Dis 2005; 191:1221-1224.
12. Sabin AB. Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Science 1959; 130:1387-1389.
13. Wolf JL, Dambrauskas R, Sharpe AH, Tier JS. Adherence to and penetration of the intestinal epithelium by reovirus type 1 in neonatal mice. Gastroenterology 1987; 92:82-91.
14. Kauffman RS, Wolf JL, Finbert R, Trier JS, Fields BN. The sigma 1 protein determines the extent of spread of reovirus from the gastrointestinal tract of mice. Virology 1983; 124:403-410.
15. Brown WR, Sokol RJ, Levin MJ, Silverman A, Tamaru T, Lilly JR, Hall RJ, Cheney M. Lack of correlation between infection with reovirus 3 and extrahepatic biliary atresia or neonatal hepatitis. J Pediatr 1988; 113:670-676.
16. Ouattara LA, Barin F, Barthez MA, Bonnaud B, Roingeard P, Goudeau A, Castelnau P, Vernet G, Paranhos-Baccala G, Komurian-Pradel F. Novel human reovirus isolated from children with acute necrotizing encephalopathy. Emerg Infect Dis 2011; 17:1436-1444.
17. Tillotson JR, Lerner AM. Reovirus type 3 associated with fatal pneumonia. N Engl J Med 1967; 276:1060-1063.
18. Kelly K, Nawrocki S, Mita A, Coffey M, Giles F, Mita M. Reovirus-based therapy for cancer. Expert Opin Biol Ther 2009; 9:817-830.
19. Veerapong J, Bickenbach KA, Shao MY, Smith KD, Posner MC, Roizman B, Weichselbaum RR. Systemic delivery of (gamma1) 34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res 2007; 67:8301-8306.
20. Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey MC, Zwiebel J, Kendra K. Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther 2012; 20:1998-2003.
21. Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nouvo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS. REO-10: A phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 2010; 16:5564-5572.
22. Gollamundi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, Coffey MC, Gill GM, Mettinger K, Miriadason JM, Mani S, Goel S. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 2010; 28:641-649.
23. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey MC, Harrington KJ. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008; 14:7127-7137.
24. Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, DeBono JS, Melcher AA. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 2010; 16:3067-3077.
25. Forsyth P, Roldan G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Matthews MV, Markert J, Gillespie Y, Coffey MC, Thompson B, Hamilton M. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 2008; 16:627-632.
26. Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V, Twigger K, Coffey MC, Mettingger K, Gil G, Evans TRJ, de Bono JS. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 2011; 17:581-588.
27. Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, Thompson J, Selby P, de Bono J, Melcher A, Pandha H, Coffey MC, Vile R, Harrington K. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008; 14:259-269.
28. Black AJ, Morris DG. Clinical trials involving the oncolytic virus, reovirus: ready for prime time. Expert Rev Clin Pharmacol 2012; 5:517-520.
29. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
30. Coffey MC, Strong JE, Forsyth PA, Lee PWK. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282:1332-1334.
31. Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Moffey M, Giles FJ, Carew JS, Nawrocki ST. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene 2012; 31:3023-3038.
32. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington K, DeBono JS. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008; 14:7127-7137.
33. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012; 18:2080-2089.
34. Adair RA, Scott KJ, Fraser S, Errington-Mais F, Pandha H, Coffey M, Selby P, Cook GP, Vile R, Harrington RJ, Toogood G, Melcher AA. Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer 2013; 132:2327-2338.
35. Morris DG, Feng X, DiFrancesco LM, Fonseca K, Forsyth PA, Paterson AH, Coffey MC, Thompson B. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin(R)) in patients with advanced solid tumors. Invest New Drugs 2013; 31:696-706.
36. Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther 2014; 22:1056-1062.
37. Kyula JN, Roulstone V, Karapanagiotou EM, Melcher AA, Harrington KJ. Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer. Expert Opin Biol Ther 2012; 12:1669-1678.
38. Hingorani P, Zhang W, Lin J, Liu L, Guha C, Kolb EA. Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts. Cancer 2011; 117:1764-1774.
39. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Cesne AL, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD4 + CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-648.
40. Smakman N, van der Bilt JDW, van den Wollenberg DJM, Borel Rinkes IHM, Kranenburg O. Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther 2006; 13:815-818.